iRhythm Holdings, Inc. (IRTC) has a MoatMap StockRank of 30/100 based on Quality (49/100), Value (38/100), and Momentum (31/100) factor scores. The current signal is SELL. iRhythm Holdings offers an innovative ambulatory ECG monitoring solution with strong consumer appeal, but its lack of consistent profitability and ongoing regulatory/reimbursement headwinds fail our Warren Buffett margin of safety filter.
iRhythm Holdings, Inc. develops and commercializes Zio, a wearable biosensor and AI-powered platform for the diagnosis of cardiac arrhythmias, providing extended continuous cardiac monitoring services. It is a market leader in ambulatory cardiac monitoring, leveraging proprietary, patient-friendly technology and a robust AI-driven analytics platform. The company benefits from strong clinical evidence and established reimbursement pathways.
| Price | $113.83 |
| Market Cap | $3.8B |
| P/E (Forward) | 102.11 |
| Price/Book | 21.88 |
| Return on Equity | -22.4% |
| Return on Invested Capital | -3.5% |
| Debt/Equity | 452.39 |
| Gross Margin | 71.0% |
| Operating Margin | -5.9% |
| Revenue Growth | 25.7% |
| Free Cash Flow | $57M |
iRhythm Holdings, Inc. operates in the Medical Devices industry, part of the Healthcare sector (United States).